Cervical cancer (CC) caused by human papillomavirus (HPV) is one of the largest causes of
malignancies in women worldwide. Cisplatin is one of the widely used drugs for the …

Cervical cancer (CC) is the fourth leading cause of cancer death (~ 324,000 deaths
annually) among women internationally, with 85% of these deaths reported in developing …

Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year
survival is only 10%–20%. Chemotherapy is considered as the standard treatment for …

Abstract Treatment failure is one of the main hurdles in treating cervical cancer, despite
significant breakthroughs in both conventional and targeted therapy. The one-year survival …

Head and neck squamous cell carcinomas (HNSCCs) are the eighth most common cancers
worldwide. While promising new therapies are emerging, cisplatin-based chemotherapy …

Background: Cervical cancer is one of the most common gynecological cancers worldwide.
The tumor microenvironment significantly influences the therapeutic response and clinical …

Cancer cells utilise several mechanisms to increase their survival and progression as well
as their resistance to anticancer therapy: deregulation of growth regulatory pathways by …

Although cisplatin has been a pivotal chemotherapy drug in treating patients with various
types of cancer for decades, drug resistance has been a major clinical impediment. In …

Head and neck squamous cell carcinoma (HNSCC) arises from the interplay of multiple
factors, such as smoking, alcohol consumption, and viral infections. Cisplatin-based …

Cisplatin is a platinum-based chemotherapeutic drug used in the standard treatment of
various solid cancers including testicular, bladder, head and neck, cervical and ovarian …